EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 3.0

Germline Pathogenic Variant Landscape in Ductal Carcinoma in situ: Yield of Guideline-Based Testing in a Jordanian Cohort

Hikmat Abdel-Razeq iD, Faris Tamimi iD, Lulwa El Saket, Sarah Abdel-Razeq, Hira Bani Hani, Abdulrahman Shamieh, Baha Sharaf iD, Areej Al-Atary, Maryam El-Atrash, Malek Horani iD, Mahmoud Abunasser iD, Tamer Al-Batsh und 1 weitere

The Application of Clinical Genetics · 2026-11 · Volume 19 · 1-12

DOI: 10.2147/tacg.s631634 ↗

Kurz gefasst

Leitlinie in der Zeitschrift The Application of Clinical Genetics, 2026-11. Verfasst von Hikmat Abdel-Razeq und 12 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology and Medical Oncology, Department of Medicine, King Hussein Cancer Center, Amman, 11941, Jordan. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Ductal carcinoma in situ (DCIS) is a heterogeneous pre-invasive breast cancer entity in which genetic predisposition may contribute to disease development. This study evaluated the frequency and spectrum of pathogenic germline variants among Jordanian patients with DCIS who met guideline-based criteria for germline genetic testing at a single tertiary cancer centre.

Methods

We conducted a retrospective review of clinical and genetic data from patients diagnosed with DCIS. Variant classification was standardized according to American College of Medical Genetics and Genomics (ACMG) guidelines. Of 622 patients with DCIS identified during the study period, 271 (43.6%) met National Comprehensive Cancer Network (NCCN) and/or American Society of Clinical Oncology (ASCO) criteria in effect at the time of diagnosis and underwent germline genetic testing using next-generation sequencing (NGS) panels.

Results

A total of 271 patients underwent germline genetic testing. The median age at diagnosis was 47 years (range, 20– 90). Pathogenic or likely pathogenic (P/LP) variants were detected in 20 patients (7.4%; 95% CI 4.6– 11.2). BRCA2 was the most affected gene (n=9, 45.0%), followed by CHEK2 (n=3), and BRCA1, TP53 , and ATM (n=2 each). Variants of uncertain significance (VUS) were identified in 94 patients (34.7%). Patients with P/LP variants were younger at diagnosis (mean 43.7 vs 48.9 years). P/LP variants were identified in 9.5% of patients aged ≤ 50 years compared with 3.9% of those aged > 50 years (p=0.098, Fisher exact test). Prevalence was 7.4% among patients with a family history of cancer and 7.1% among those without (p=1.000). VUS prevalence rose with panel breadth, from 7.3% on a three-gene panel to 60.5% on an 84-gene panel.

Conclusion

In this criteria-eligible Jordanian DCIS cohort, the observed 7.4% prevalence of pathogenic germline variants supports genetic testing for patients with DCIS who meet established criteria. Carrier prevalence did not differ significantly by age at diagnosis or family history, and the study did not evaluate universal testing. The observed VUS rate was strongly dependent on panel breadth. Keywords: breast cancer, DCIS, ductal carcinoma in-situ, germline genetic testing, BRCA

Schlagwörter

Stichwörter der Autor:innen

BRCADCISbreast cancerductal carcinoma in-situgermline genetic testing

Autor:innen und Institutionen

  • Section of Hematology and Medical Oncology, Department of Medicine, King Hussein Cancer Center, Amman, 11941, Jordan.
  • School of Medicine, The University of Jordan, Amman, 11942, Jordan.
  • Department of Nursing, King Hussein Cancer Center, Amman, 11941, Jordan.

ORCID-Profile: Hikmat Abdel-Razeq, Faris Tamimi, Baha Sharaf, Malek Horani, Mahmoud Abunasser, Osama El Khatib

Zitieren

APA

Abdel-Razeq, H., Tamimi, F., El Saket, L., Abdel-Razeq, S., Bani Hani, H., Shamieh, A., Sharaf, B., Al-Atary, A., El-Atrash, M., Horani, M., Abunasser, M., Al-Batsh, T., & El Khatib, O. (2026). Germline Pathogenic Variant Landscape in Ductal Carcinoma in situ: Yield of Guideline-Based Testing in a Jordanian Cohort. The Application of Clinical Genetics, Volume 19, 1-12. https://doi.org/10.2147/tacg.s631634

Vancouver

Abdel-Razeq H, Tamimi F, El Saket L, Abdel-Razeq S, Bani Hani H, Shamieh A, et al. Germline Pathogenic Variant Landscape in Ductal Carcinoma in situ: Yield of Guideline-Based Testing in a Jordanian Cohort. The Application of Clinical Genetics. 2026;Volume 19:1-12. doi:10.2147/tacg.s631634

BibTeX
@article{AbdelRazeq2026,
  author = {Abdel-Razeq, Hikmat and Tamimi, Faris and El Saket, Lulwa and Abdel-Razeq, Sarah and Bani Hani, Hira and Shamieh, Abdulrahman and Sharaf, Baha and Al-Atary, Areej and El-Atrash, Maryam and Horani, Malek and Abunasser, Mahmoud and Al-Batsh, Tamer and El Khatib, Osama},
  title = {Germline Pathogenic Variant Landscape in Ductal Carcinoma in situ: Yield of Guideline-Based Testing in a Jordanian Cohort},
  journal = {The Application of Clinical Genetics},
  year = {2026},
  volume = {Volume 19},
  pages = {1--12},
  doi = {10.2147/tacg.s631634}
}
Kostenlos starten →